One Step Closer to Groundbreaking Lupus Drug, Feinstein Institutes Announces Clinical Trial Results
September 17, 2020
September 17, 2020
MANHASSET, New York, Sept. 17 (TNSRes) -- Feinstein Institutes for Medical Research issued the following news on Sept. 16:
Northwell Health's Division of Rheumatology and the Feinstein Institutes for Medical Research announced today the results from the largest Phase 3 lupus nephritis clinical trial ever conducted.
The study, known as the BLISS-LN trial, found positive results of the efficacy and safety of the drug belimumab in patients with active lupus nephritis . . .
Northwell Health's Division of Rheumatology and the Feinstein Institutes for Medical Research announced today the results from the largest Phase 3 lupus nephritis clinical trial ever conducted.
The study, known as the BLISS-LN trial, found positive results of the efficacy and safety of the drug belimumab in patients with active lupus nephritis . . .